QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.

Press

1Sep 2022

The data have finally arrived!

Are you interested in studying liver diseases? Our research platform “Health Outcomes and Risk Assessment in Chronic Liver Disease” (HERALD) constitutes a unique blend of data on healthcare visits in primary and specialty care, prescriptions, lab values, FibroScan data, information on cancer, quality of care data on diabetes, socioeconomics, migration, and cause of death for 864,077 patients recorded with a diagnosis of chronic liver disease (CLD) in the Stockholm […]

31Aug 2022

The Convini Relay Race in Stockholm

Whats your 5k PB? Last week members of our Stockholm office participated in Convinistafetten, Swedens biggest relay race. Our teams Quantifly, Quantimax and Quantifast flew past the beautiful scenery of Djurgården, and looked this happy afterwards. Well done guys! ?‍♀️?‍♂️

18Aug 2022

Persistence With Biologic Treatments in Psoriasis

Does it matter whether you use a clinical registry or administrative database to calculate drug persistence rates?

The answer is yes! Colleagues from The Janssen Pharmaceutical Companies of Johnson & JohnsonQuantify Research and our CEO Kirk Geale recently published a literature review in the Journal of Drugs in Dermatology (JDD) examining the systematic differences in biologic drug persistence rates when […]